Aaron L Sverdlov

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8397087/publications.pdf

Version: 2024-02-01

84 2,345 23 45 papers citations h-index g-index

85 85 85 3717 all docs docs citations times ranked citing authors

#	Article	IF	Citations
1	Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE) Tj ETQq $1\ 1\ 0$.784314 13.7	rgBT (Oyerloc
2	Status of cardioâ€oncology in Australia in 2021: a nationwide multidisciplinary survey. Internal Medicine Journal, 2022, 52, 341-342.	0.8	2
3	Patterns of contraceptive use among young Australian women with chronic disease: findings from a prospective cohort study. Reproductive Health, 2022, 19, 111.	3.1	6
4	Management of Acute Coronary Syndromes in Patients in Rural Australia. JAMA Cardiology, 2022, 7, 690.	6.1	5
5	Patient characteristics, short-term and long-term outcomes after incident heart failure admissions in a regional Australian setting. Open Heart, 2022, 9, e001897.	2.3	2
6	International consensus statement on the management of cardiovascular risk of Bruton's tyrosine kinase inhibitors in CLL. Blood Advances, 2022, 6, 5516-5525.	5 . 2	11
7	Cardiotoxicity of Radiation Therapy: Mechanisms, Management, and Mitigation. Current Treatment Options in Oncology, 2021, 22, 70.	3.0	15
8	Effects of lockdown on acute coronary syndrome incidence in an area without community transmission of COVID-19. Open Heart, 2021, 8, e001692.	2.3	2
9	Heart failure outcomes in Aboriginal and Torres Strait Islander peoples in the Hunter New England region of New South Wales. International Journal of Cardiology, 2021, 334, 65-71.	1.7	5
10	Investigating the efficacy of chest pressure for direct current cardioversion in atrial fibrillation: a randomised control trial protocol (Pressure-AF). Open Heart, 2021, 8, e001739.	2.3	1
11	1465Adverse cardiovascular events after cancer in Queensland, Australia. International Journal of Epidemiology, 2021, 50, .	1.9	O
12	Digital Technologies to Help Delivery of Cardio–Oncology Care. Heart Lung and Circulation, 2021, 30, 1271-1273.	0.4	0
13	The Importance of Primary Care in Cardio-Oncology. Current Treatment Options in Oncology, 2021, 22, 107.	3.0	7
14	Adipose-targeted overexpression of mitochondrial-targeted catalase does not improve cardio-metabolic parameters in mice with diet-induced obesity. European Heart Journal, 2021, 42, .	2.2	O
15	Heart Failure in Breast Cancer Survivors: Focus on Early Detection and Novel Biomarkers. Current Heart Failure Reports, 2021, 18, 362-377.	3.3	4
16	Oxidative Stress in Heart Failure. , 2020, , 115-126.e6.		О
17	Suboptimal Use of Cardioprotective Medications in Patients With a History of Cancer. JACC: CardioOncology, 2020, 2, 312-315.	4.0	13
18	OUTCOMES OF HEART FAILURE AND ACUTE CORONARY SYNDROME IN INDIGENOUS POPULATION IN A REGIONAL AUSTRALIAN SETTING. Journal of the American College of Cardiology, 2020, 75, 3464.	2.8	O

#	Article	IF	CITATIONS
19	Factors Associated with Adverse Cardiovascular Events in Cancer Patients Treated with Bevacizumab. Journal of Clinical Medicine, 2020, 9, 2664.	2.4	16
20	Pulmonary Hypertension Due to Left Heart Disease. Hypertension, 2020, 75, 1397-1408.	2.7	56
21	therapies: a position statement and new risk assessment tools from the <scp>C</scp> ardioâ€ <scp>O</scp> ncology <scp>S</scp> tudy <scp>G</scp> roup of the <scp>H</scp> eart <scp>F</scp> ailure <scp>A</scp> sociation of the <scp>E</scp> uropean <scp>S</scp> ociety of <scp>C</scp> ardiology in collaboration with the <scp>I</scp> nternational	7.1	364
22	CSCP>CK/SCP>ardloa€KSCP>OK/SCP>ncology KSCP>SK/SCP>ncology KSCP>SK/SCP>ncolety. European Journal of Heart Failure, 2020, Nexus of Cancer and Cardiovascular Disease for Australia's First Peoples. JCO Global Oncology, 2020, 6, 115-119.	1.8	6
23	Ibrutinibâ€related atrial fibrillation: A single center Australian experience. Asia-Pacific Journal of Clinical Oncology, 2019, 15, e187-e190.	1.1	6
24	Anthracycline-Induced Cardiotoxicity: Time to Focus on Cardioprotection Again. Heart Lung and Circulation, 2019, 28, 1454-1456.	0.4	2
25	Predicting Events in Heart Failure Patients: An Ongoing Challenge. Heart Lung and Circulation, 2019, 28, 195-197.	0.4	1
26	Heart failure admissions following <scp>ST</scp> segment elevation myocardial infarction. Australian Journal of Rural Health, 2019, 27, 99-100.	1.5	2
27	Cardiovascular Outcomes in Indigenous Australians: A National Gap. Heart Lung and Circulation, 2019, 28, 825-826.	0.4	3
28	Energetic Dysfunction Is Mediated by Mitochondrial Reactive Oxygen Species and Precedes Structural Remodeling in Metabolic Heart Disease. Antioxidants and Redox Signaling, 2019, 31, 539-549.	5.4	20
29	The Role of Pathological Aging in Cardiac and Pulmonary Fibrosis. , 2019, 10, 419.		59
30	Galectinâ€3 Is Associated With Stage B Metabolic Heart Disease and Pulmonary Hypertension in Young Obese Patients. Journal of the American Heart Association, 2019, 8, e011100.	3.7	19
31	Premature Ventricular Complexes: Benign, Pathogenic or Just a Marker of Myocardial Disease?. Heart Lung and Circulation, 2019, 28, 351-353.	0.4	5
32	Oxidative modifications of mitochondrial complex II are associated with insulin resistance of visceral fat in obesity. American Journal of Physiology - Endocrinology and Metabolism, 2019, 316, E168-E177.	3.5	25
33	Decreased ATP production and myocardial contractile reserve in metabolic heart disease. Journal of Molecular and Cellular Cardiology, 2018, 116, 106-114.	1.9	70
34	Outcomes following heart failure hospitalization in a regional Australian setting between 2005 and 2014. ESC Heart Failure, 2018, 5, 271-278.	3.1	22
35	ABCB10 deletion in cardiomyocytes leads to mitochondrial dysfunction and early death. Free Radical Biology and Medicine, 2018, 128, S22.	2.9	0
36	Increased risk of atrial fibrillation among patients undergoing coronary artery bypass graft surgery while receiving nitrates and antiplatelet agents. Journal of International Medical Research, 2018, 46, 3183-3194.	1.0	3

#	Article	IF	CITATIONS
37	Response to the letter to editor: Galectin-3 and atrial fibrillation. International Journal of Cardiology, 2017, 229, 2.	1.7	O
38	Vitamin D supplementation lowers thrombospondin-1 levels and blood pressure in healthy adults. PLoS ONE, 2017, 12, e0174435.	2.5	13
39	Interplay between Oxidative Stress and Inflammation in Cardiometabolic Syndrome. Mediators of Inflammation, 2016, 2016, 1-3.	3.0	25
40	Follistatin-like 3 is Elevated in Acute Heart Failure Patients. Heart Lung and Circulation, 2016, 25, S109-S110.	0.4	1
41	Follistatin-like 3 Predicts Aortic Root Enlargement in Patients with Bicuspid Aortic Valve. Heart Lung and Circulation, 2016, 25, S77-S78.	0.4	0
42	New onset atrial fibrillation is associated with elevated galectin-3 levels. International Journal of Cardiology, 2016, 223, 48-49.	1.7	19
43	Elevated parathyroid hormone predicts high asymmetric dimethylarginine (ADMA) concentrations in obese diabetic patients. Diabetes and Metabolism, 2016, 42, 378-381.	2.9	3
44	Galectin 3 is Markedly Elevated in Severe Heart Failure and Predicts Improvement in LV Volumes Post Cardiac Resynchronisation Therapy. Heart Lung and Circulation, 2016, 25, S110.	0.4	0
45	Mitochondrial Reactive Oxygen Species Mediate Cardiac Structural, Functional, and Mitochondrial Consequences of Dietâ€Induced Metabolic Heart Disease. Journal of the American Heart Association, 2016, 5, .	3.7	85
46	Partial Liver Kinase B1 (LKB1) Deficiency Promotes Diastolic Dysfunction, De Novo Systolic Dysfunction, Apoptosis, and Mitochondrial Dysfunction With Dietary Metabolic Challenge. Journal of the American Heart Association, 2016, 5, .	3.7	5
47	Mitochondrial remodeling in mice with cardiomyocyte-specific lipid overload. Journal of Molecular and Cellular Cardiology, 2015, 79, 275-283.	1.9	52
48	Poster Session 1: Sunday 3 May 2015, 08:30-18:00 * Room: Poster Area. European Heart Journal Cardiovascular Imaging, 2015, 16, i11-i28.	1.2	2
49	High fat, high sucrose diet causes cardiac mitochondrial dysfunction due in part to oxidative post-translational modification of mitochondrial complex II. Journal of Molecular and Cellular Cardiology, 2015, 78, 165-173.	1.9	68
50	Overexpression of Catalase Diminishes Oxidative Cysteine Modifications of Cardiac Proteins. PLoS ONE, 2015, 10, e0144025.	2.5	31
51	Effects of acute hyperglycaemia on cardiovascular homeostasis: does a spoonful of sugar make the flow-mediated dilatation go down?. Journal of Thoracic Disease, 2015, 7, E607-11.	1.4	3
52	Aging of Platelet Nitric Oxide Signaling: Pathogenesis, Clinical Implications, and Therapeutics. Seminars in Thrombosis and Hemostasis, 2014, 40, 660-668.	2.7	13
53	Aging of the Nitric Oxide System: Are We as Old as Our NO?. Journal of the American Heart Association, 2014, 3, .	3.7	67
54	Thioredoxin-Interacting Protein: Pathophysiology and Emerging Pharmacotherapeutics in Cardiovascular Disease and Diabetes. Cardiovascular Drugs and Therapy, 2014, 28, 347-360.	2.6	76

#	Article	IF	CITATIONS
55	Quantitative interpretation of FDG PET/CT with myocardial perfusion imaging increases diagnostic information in the evaluation of cardiac sarcoidosis. Journal of Nuclear Cardiology, 2014, 21, 925-939.	2.1	155
56	Abstract 12622: Western Diet for One Month Impairs Myocardial Energetics and Both Systolic and Diastolic Pump Function in the Mouse Heart. Circulation, 2014, 130, .	1.6	1
57	Premature Aging of Cardiovascular/Platelet Function in Polycystic Ovarian Syndrome. American Journal of Medicine, 2013, 126, 640.e1-640.e7.	1.5	11
58	The nitric oxide redox sibling nitroxyl partially circumvents impairment of platelet nitric oxide responsiveness. Nitric Oxide - Biology and Chemistry, 2013, 35, 72-78.	2.7	23
59	Reciprocal regulation of NO signaling and TXNIP expression in humans: Impact of aging and ramipril therapy. International Journal of Cardiology, 2013, 168, 4624-4630.	1.7	36
60	Impact of chronic congestive heart failure on pharmacokinetics and vasomotor effects of infused nitrite. British Journal of Pharmacology, 2013, 169, 659-670.	5.4	21
61	Enhanced NO Signaling in Patients with Takotsubo Cardiomyopathy: Short-Term Pain, Long-Term Gain?. Cardiovascular Drugs and Therapy, 2013, 27, 541-547.	2.6	32
62	Heart Failure. Hypertension, 2013, 61, 284-285.	2.7	15
63	Elevated parathyroid hormone predicts high asymmetric dimethylarginine (ADMA) concentrations; independent of vitamin D status. European Heart Journal, 2013, 34, P613-P613.	2.2	1
64	Slowly resolving global myocardial inflammation/oedema in Tako-Tsubo cardiomyopathy: evidence from T2-weighted cardiac MRI. Heart, 2012, 98, 1278-1284.	2.9	100
65	Determinants of aortic sclerosis progression: implications regarding impairment of nitric oxide signalling and potential therapeutics. European Heart Journal, 2012, 33, 2419-2425.	2.2	29
66	Can we make sense of takotsubo cardiomyopathy? An update on pathogenesis, diagnosis and natural history. Expert Review of Cardiovascular Therapy, 2012, 10, 215-221.	1.5	19
67	Redefining the natural history of calcific aortic stenosis: lessons from Laennec. Journal of Internal Medicine, 2012, 271, 569-572.	6.0	1
68	Prevention of aortic valve stenosis: A realistic therapeutic target?., 2012, 135, 78-93.		19
69	Pathogenesis of aortic sclerosis: association with low BMI, tissue nitric oxide resistance, but not systemic inflammatory activation. American Journal of Cardiovascular Disease, 2012, 2, 43-9.	0.5	6
70	Lack of association between aortic sclerosis and left ventricular hypertrophy in elderly subjects. International Journal of Cardiology, 2011, 150, 33-38.	1.7	9
71	The endogenous NOS inhibitor asymmetric dimethylarginine (ADMA) predicts LV mass independent of afterload. Nitric Oxide - Biology and Chemistry, 2011, 25, 41-46.	2.7	14
72	Determinants of insulin responsiveness in young women: Impact of polycystic ovarian syndrome, nitric oxide, and vitamin D. Nitric Oxide - Biology and Chemistry, 2011, 25, 326-330.	2.7	66

#	Article	IF	CITATIONS
73	Effects of Aging, Renal Dysfunction, Left Ventricular Systolic Impairment, and Weight on Steady State Pharmacokinetics of Perhexiline. Therapeutic Drug Monitoring, 2011, 33, 251-256.	2.0	5
74	Ramipril retards development of aortic valve stenosis in a rabbit model: mechanistic considerations. British Journal of Pharmacology, 2011, 162, 722-732.	5.4	35
75	N-Terminal Pro-Brain Natriuretic Protein Levels in Takotsubo Cardiomyopathy. American Journal of Cardiology, 2011, 108, 1316-1321.	1.6	123
76	Pathogenesis of aortic stenosis: not just a matter of wear and tear. American Journal of Cardiovascular Disease, $2011, 1, 185-99$.	0.5	25
77	Modulation of myocardial metabolism: an emerging therapeutic principle. Current Opinion in Cardiology, 2010, 25, 329-334.	1.8	46
78	Hydralazine does not Ameliorate Nitric Oxide Resistance in Chronic Heart Failure. Cardiovascular Drugs and Therapy, 2010, 24, 131-137.	2.6	10
79	Does Vitamin D Modulate Asymmetric Dimethylarginine and C-Reactive Protein Concentrations?. American Journal of Medicine, 2010, 123, 335-341.	1.5	108
80	Determinants of Occurrence of Aortic Sclerosis in an Aging Population. JACC: Cardiovascular Imaging, 2009, 2, 919-927.	5.3	47
81	Correlates of arterial stiffness in an ageing population: Role of asymmetric dimethylarginine. Pharmacological Research, 2009, 60, 503-507.	7.1	13
82	Management of the metabolic syndrome in cardiovascular disease. Current Treatment Options in Cardiovascular Medicine, 2008, 10, 27-38.	0.9	1
83	Vitamin D2 supplementation induces the development of aortic stenosis in rabbits: Interactions with endothelial function and thioredoxin-interacting protein. European Journal of Pharmacology, 2008, 590, 290-296.	3.5	37
84	Cardiac Magnetic Resonance Imaging Identifies the Elusive Perivalvular Abscess. Circulation, 2008, 118, e1-3.	1.6	10